Research Study

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis
Principal Investigator 
Baljinder Salh

Overview

Body Locations and Systems 
Ulcerative Colitis
ClinicalTrials.gov# 
NCT03518086
Status 
Recruiting
Study Start/End 
Jan 16, 2019 to Sep 7, 2020
Locations 
Diamond Health Care Centre
Name/Title 
Jo-Ann Ford, Clinical Research Coordinator
Phone 
604-875-5705
Email Address 
jo-ann.ford@vch.ca
Purpose of Study 

 

The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.

Eligibility 

Visit ClinicalTrials.gov for your information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.